Abstract 4904
Background
Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression in NS have the potential to provide novel targets for drug development. We hypothesized that there will be a difference in genomic profile of mUC in NS vs PCS.
Methods
Tumour tissue undergoing comprehensive genomic profiling (CGP) from patients with mUC were included from NS and age matched PCS within the same time period (2014-19). Clinical and CGP data were retrospectively collected. CGP was performed using FoundationOne (Foundation Medicine, Cambridge, MA), which provides exonic coverage of 315 genes.
Results
See table.Table:
943P
Non-smoker | Smoker | P value | |
---|---|---|---|
Median age at diagnosis, years (range) | 66.5 (33-86) | 67 (35-85) | 0.94 |
Site of primary | 0.009 | ||
Bladder | 37 (80%) | 39 (100%) | |
Upper tract | 9 (19.6%) | 0 | |
Urethral | 1 (<1%) | 0 | |
Gender | 0.001 | ||
Male | 32 | 38 | |
Female | 14 | 1 | |
Median number of genomic alterations (range) | 7 (1-17) | 7 (1-18) | 0.26 |
MLL2 gene alteration | 11 | 1 | 0.01 |
Conclusions
While the overall number of genomic alteration per patient and alteration frequencies were similar in NS vs PCS, we found a significantly higher frequency of MLL2 alterations in NS (p < 0.05). This finding is in agreement with previous reports of MLL2 alterations in UC; however, its significantly higher prevalence in NS is a novel finding and may suggest different oncogenic pathways in NS. It’s interesting to note that MLL2 alterations have been reported as drivers of self-renewal in bladder cancer stem cells (Yang et al, Euro Urol 2017, PMID 27387124).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Huntsman Cancer Institute.
Funding
Has not received any funding.
Disclosure
B.L. Maughan: Advisory / Consultancy: Peloton Therapeutics; Advisory / Consultancy: BMS; Advisory / Consultancy: Tempus; Advisory / Consultancy: Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Astellas Pharma. N. Agarwal: Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Exelixis; Honoraria (institution), Advisory / Consultancy: Eisai; Honoraria (institution), Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Foundation One; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Medivation; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Nektar; Honoraria (institution), Advisory / Consultancy: Genentech; Honoraria (institution), Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Pharmacyclics; Honoraria (institution): Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract